Cervical cancer benefits from trabectedin combination with the β-blocker propranolol: in vitro and ex vivo evaluations in patient-derived organoids

Cervical cancer benefits from trabectedin combination with the β-blocker propranolol: in vitro and ex vivo evaluations in patient-derived organoids

Background: Cervical cancer (CC) is characterized by genomic alterations in DNA repair genes, which could favor treatment with agents causing DNA double-strand breaks (DSBs), such as trabectedin. Hence, we evaluated the capability of trabectedin to inhibit CC viability and used ovarian cancer (OC) m...

Full description

Bibliographic Details
Main Authors: Roberta Di Fonte, Sabino Strippoli, Marianna Garofoli, Gennaro Cormio, Simona Serratì, Vera Loizzi, Rossella Fasano, Francesca Arezzo, Mariateresa Volpicella, Afshin Derakhshani, Michele Guida, Letizia Porcelli, Amalia Azzariti
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-06-01
Series:Frontiers in Cell and Developmental Biology
Subjects:
cervical cancer
trabectedin
propranolol
ovarian cancer
patient-derived organoids
Online Access:https://www.frontiersin.org/articles/10.3389/fcell.2023.1178316/full

Internet

https://www.frontiersin.org/articles/10.3389/fcell.2023.1178316/full

Similar Items